Age-associated evolution of plasmatic amyloid in mouse lemur primates: Relationship with intracellular amyloid deposition

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 149-156

  Roy, Maggie ^a,b,c   Cardoso, Cécile ^a,b   Dorieux, Olène ^a,b,d   Malgorn, Carole ^a,b   Epelbaum, Stéphane ^e,f,g,h   Petit, Fanny ^a,b   Kraska, Audrey ^a,b   Brouillet, Emmanuel ^a,b   Delatour, Benoît ^e,f,g,h   Perret, Martine ^d   Aujard, Fabienne ^d   Dhenain, Marc ^a,b  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d MNHN   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f INSERM   (France)

^g INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^h ICM   (France)

Author keywords

Alzheimer; Amyloid; Cerebral aging; Intracellular amyloid; Lemur; Microcebus murinus; Plasma

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

AGED; AGING; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CAUDATE NUCLEUS; CELL DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; HIPPOCAMPUS; HISTOLOGY; MEYNERT BASAL NUCLEUS; MOUSE LEMUR; NERVE CELL; NONHUMAN; PARIETAL CORTEX; ALZHEIMER DISEASE; ANIMAL; BLOOD; BRAIN; CHEIROGALEIDAE; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOMARKERS; BRAIN; CHEIROGALEIDAE; DISEASE MODELS, ANIMAL; INTRACELLULAR SPACE; NEURONS;

EID: 84920588035     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.07.017     Document Type: Article

References (62)

1. Aho L., Pikkarainen M., Hiltunen M., Leinonen V., Alafuzoff I. Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J.Alzheimers Dis. 2010, 20:1015-1028.
2. Alafuzoff I., Pikkarainen M., Arzberger T., Thal D.R., Al-Sarraj S., Bell J., Bodi I., Budka H., Capetillo-Zarate E., Ferrer I., Gelpi E., Gentleman S., Giaccone G., Kavantzas N., King A., Korkolopoulou P., Kovacs G.G., Meyronet D., Monoranu C., Parchi P., Patsouris E., Roggendorf W., Stadelmann C., Streichenberger N., Tagliavini F., Kretzschmar H. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2008, 115:533-546.
3. Alafuzoff I., Thal D.R., Arzberger T., Bogdanovic N., Al-Sarraj S., Bodi I., Boluda S., Bugiani O., Duyckaerts C., Gelpi E., Gentleman S., Giaccone G., Graeber M., Hortobagyi T., Hoftberger R., Ince P., Ironside J.W., Kavantzas N., King A., Korkolopoulou P., Kovacs G.G., Meyronet D., Monoranu C., Nilsson T., Parchi P., Patsouris E., Pikkarainen M., Revesz T., Rozemuller A., Seilhean D., Schulz-Schaeffer W., Streichenberger N., Wharton S.B., Kretzschmar H. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009, 117:309-320.
4. Andreasen N., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 1999, 56:673-680.
5. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
6. Bolte S., Cordelieres F.P. Aguided tour into subcellular colocalization analysis in light microscopy. J.Microsc. 2006, 224:213-232.
7. Bons N., Mestre N., Petter A. Senile plaques and neurofibrillary changes in the brain of an aged lemurian primate, Microcebus murinus. Neurobiol. Aging 1991, 13:99-105.
8. Bons N., Sihol S., Barbier V., Mestre-Frances N., Albe-Fessard D. Astereotaxic atlas of the grey lesser mouse lemur brain (Microcebus murinus). Brain Res. Bull. 1998, 46:1-173.
9. Buerger K., Frisoni G., Uspenskaya O., Ewers M., Zetterberg H., Geroldi C., Binetti G., Johannsen P., Rossini P.M., Wahlund L.O., Vellas B., Blennow K., Hampel H. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp. Gerontol. 2009, 44:579-585.
10. Casas C., Sergeant N., Itier J.M., Blanchard V., Wirths O., van der Kolk N., Vingtdeux V., van de Steeg E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T.A., Benoit P., Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 2004, 165:1289-1300.
11. Chang W.P., Koelsch G., Wong S., Downs D., Da H., Weerasena V., Gordon B., Devasamudram T., Bilcer G., Ghosh A.K., Tang J. Invivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J.Neurochem. 2004, 89:1409-1416.
12. Craft D.L., Wein L.M., Selkoe D.J. Amathematical model of the impact of novel treatments on the Abeta burden in the Alzheimer's brain, CSF and plasma. Bull. Math. Biol. 2002, 64:1011-1031.
13. Cuello A.C., Allard S., Ferretti M.T. Evidence for the accumulation of Abeta immunoreactive material in the human brain and in transgenic animal models. Life Sci. 2012, 91:1141-1147.
14. Das R., Nachbar R.B., Edelstein-Keshet L., Saltzman J.S., Wiener M.C., Bagchi A., Bailey J., Coombs D., Simon A.J., Hargreaves R.J., Cook J.J. Modeling effect of a gamma-secretase inhibitor on amyloid-beta dynamics reveals significant role of an amyloid clearance mechanism. Bull. Math. Biol. 2011, 73:230-247.
15. Delatour B., Mercken L., El Hachimi K.H., Colle M.A., Pradier L., Duyckaerts C. FE65 in Alzheimer's disease: neuronal distribution and association with neurofibrillary tangles. Am. J. Pathol. 2001, 158:1585-1591.
16. Devanand D.P., Schupf N., Stern Y., Parsey R., Pelton G.H., Mehta P., Mayeux R. Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment. Neurology 2011, 77:125-131.
17. Duyckaerts C., Potier M.C., Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:5-38.
18. Faure A., Verret L., Bozon B., El Tannir El Tayara N., Ly M., Kober F., Dhenain M., Rampon C., Delatour B. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol. Aging 2011, 32:407-418.
19. Fleisher A.S., Raman R., Siemers E.R., Becerra L., Clark C.M., Dean R.A., Farlow M.R., Galvin J.E., Peskind E.R., Quinn J.F., Sherzai A., Sowell B.B., Aisen P.S., Thal L.J. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 2008, 65:1031-1038.
20. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006, 24:516-524.
21. Gonzalez-Martinez A., Rosado B., Pesini P., Suarez M.L., Santamarina G., Garcia-Belenguer S., Villegas A., Monleon I., Sarasa M. Plasma beta-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. Exp. Gerontol. 2011, 46:590-596.
22. Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H., Greengard P., Relkin N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156:15-20.
23. Gyure K.A., Durham R., Stewart W.F., Smialek J.E., Troncoso J.C. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 2001, 125:489-492.
24. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
25. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
26. Joseph-Mathurin N., Dorieux O., Trouche S., Boutajangout A., Kraska A., Fontès P., Verdier J.-M., Sigurdsson E.M., Mestre-Francés N., Dhenain M. Aβ immunization in old mouse lemur primates induces cerebral microhemorrhages and accelerates age-associated iron deposits in the choroid plexus. Neurobiol. Aging 2013, 34:2613-2622.
27. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J.Neurosci. 2001, 21:372-381.
28. Kounnas M.Z., Danks A.M., Cheng S., Tyree C., Ackerman E., Zhang X., Ahn K., Nguyen P., Comer D., Mao L., Yu C., Pleynet D., Digregorio P.J., Velicelebi G., Stauderman K.A., Comer W.T., Mobley W.C., Li Y.M., Sisodia S.S., Tanzi R.E., Wagner S.L. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010, 67:769-780.
29. Kraska A., Dorieux O., Picq J.-L., Petit F., Bourrin E., Chenu E., Volk A., Perret M., Hantraye P., Mestre-Frances N., Aujard F., Dhenain M. Age associated cerebral atrophy in mouse lemur primates. Neurobiol. Aging 2011, 32:894-906.
30. Kulstad J.J., McMillan P.J., Leverenz J.B., Cook D.G., Green P.S., Peskind E.R., Wilkinson C.W., Farris W., Mehta P.D., Craft S. Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J.Neuropathol. Exp. Neurol. 2005, 64:139-146.
31. Kuo Y.M., Kokjohn T.A., Watson M.D., Woods A.S., Cotter R.J., Sue L.I., Kalback W.M., Emmerling M.R., Beach T.G., Roher A.E. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am. J. Pathol. 2000, 156:797-805.
32. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J.Neurosci. 2004, 24:10191-10200.
33. Lanz T.A., Wood K.M., Richter K.E., Nolan C.E., Becker S.L., Pozdnyakov N., Martin B.A., Du P., Oborski C.E., Wood D.E., Brown T.M., Finley J.E., Sokolowski S.A., Hicks C.D., Coffman K.J., Geoghegan K.F., Brodney M.A., Liston D., Tate B. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J.Pharmacol. Exp. Ther. 2010, 334:269-277.
34. Lee E.B., Skovronsky D.M., Abtahian F., Doms R.W., Lee V.M. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J.Biol. Chem. 2003, 278:4458-4466.
35. Lemere C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 2009, 175:83-93.
36. Lemere C.A., Beierschmitt A., Iglesias M., Spooner E.T., Bloom J.K., Leverone J.F., Zheng J.B., Seabrook T.J., Louard D., Li D., Selkoe D.J., Palmour R.M., Ervin F.R. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 2004, 165:283-297.
37. Liu L., Duff K. Atechnique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J.Vis. Exp. 2008, e960. http://www.jove.com/index/Details.stp?ID=960.
38. Lopez O.L., Kuller L.H., Mehta P.D., Becker J.T., Gach H.M., Sweet R.A., Chang Y.F., Tracy R., DeKosky S.T. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 2008, 70:1664-1671.
39. Mestre-Frances N., Keller E., Calenda A., Barelli H., Checler F., Bons N. Immunohistochemical analysis of cerebral cortical and vascular lesions in the primate Microcebus murinus reveal distinct amyloid beta 1-42 and beta 1-40 immunoreactivity profiles. Neurobiol. Dis. 2000, 7:1-8.
40. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., Olson D., Southwick P., Wolfert R., Munroe B., Lieberburg I., Seubert P., Schenk D. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995, 38:643-648.
41. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J.Neurosci. 2006, 26:10129-10140.
42. Picq J.L., Aujard F., Volk A., Dhenain M. Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments. Neurobiol. Aging 2012, 33:1096-1109.
43. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 2009, 30:1728-1736.
44. Roher A.E., Esh C.L., Kokjohn T.A., Castano E.M., Van Vickle G.D., Kalback W.M., Patton R.L., Luehrs D.C., Daugs I.D., Kuo Y.M., Emmerling M.R., Soares H., Quinn J.F., Kaye J., Connor D.J., Silverberg N.B., Adler C.H., Seward J.D., Beach T.G., Sabbagh M.N. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009, 5:18-29.
45. Sauvee M., DidierLaurent G., Latarche C., Escanye M.C., Olivier J.L., Malaplate-Armand C. Additional use of abeta42/abeta40 ratio with cerebrospinal fluid biomarkers p-tau and abeta42 increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. J.Alzheimers Dis. 2014, 41:377-386.
46. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192:106-113.
47. Sharman M.J., Morici M., Hone E., Berger T., Taddei K., Martins I.J., Lim W.L., Singh S., Wenk M.R., Ghiso J., Buxbaum J.D., Gandy S., Martins R.N. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. J.Alzheimers Dis. 2010, 21:403-409.
48. Slaets S., Le Bastard N., Martin J.J., Sleegers K., Van Broeckhoven C., De Deyn P.P., Engelborghs S. Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J.Alzheimers Dis. 2013, 36:759-767.
49. Sobow T., Flirski M., Kloszewska I., Liberski P.P. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol. Exp. 2005, 65:117-124.
50. Song F., Poljak A., Valenzuela M., Mayeux R., Smythe G.A., Sachdev P.S. Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease. J.Alzheimers Dis. 2011, 25:1-11.
51. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's Dement. 2011, 7:280-292.
52. Strozyk D., Blennow K., White L.R., Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
53. Trouche S.G., Asuni A., Rouland S., Wisniewski T., Frangione B., Verdier J.M., Sigurdsson E.M., Mestre-Frances N. Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine 2009, 27:957-964.
54. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10831-10839.
55. Wang A., Das P., Switzer R.C., Golde T.E., Jankowsky J.L. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J.Neurosci. 2011, 31:4124-4136.
56. West M.J., Slomianka L., Gundersen H.J.G. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 1991, 231:482-497.
57. Wiltfang J., Esselmann H., Bibl M., Hull M., Hampel H., Kessler H., Frolich L., Schroder J., Peters O., Jessen F., Luckhaus C., Perneczky R., Jahn H., Fiszer M., Maler J.M., Zimmermann R., Bruckmoser R., Kornhuber J., Lewczuk P. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J.Neurochem. 2007, 101:1053-1059.
58. Winton M.J., Lee E.B., Sun E., Wong M.M., Leight S., Zhang B., Trojanowski J.Q., Lee V.M. Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: implications for tau versus Abeta-mediated Alzheimer neurodegeneration. J.Neurosci. 2011, 31:7691-7699.
59. Wirths O., Dins A., Bayer T.A. AbetaPP accumulation and/or intraneuronal amyloid-beta accumulation? The 3xTg-AD mouse model revisited. J.Alzheimers Dis. 2012, 28:897-904.
60. Wirths O., Multhaup G., Czech C., Blanchard V., Moussaoui S., Tremp G., Pradier L., Beyreuther K., Bayer T.A. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 2001, 306:116-120.
61. Wirths O., Multhaup G., Bayer T.A. Amodified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J.Neurochem. 2004, 91:513-520.
62. Yamada K., Yabuki C., Seubert P., Schenk D., Hori Y., Ohtsuki S., Terasaki T., Hashimoto T., Iwatsubo T. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J.Neurosci. 2009, 29:11393-11398.